XOMA Royalty Stock Quote XOMA - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

26.97

Bid

25.00

Ask

30.00

Volume

26,063

26.50 Day's Range 27.05

13.48 52 Week Range 27.36

Market Cap

314.241M

Previous Close

27.00

Open

27.00

Last Trade

628

26.97

(priorref)

Last Trade Time

Financial Volume

$ 701,467

VWAP

26.9143

Average Volume (3m)

17,897

Shares Outstanding

11,638,553

Dividend Yield

PE Ratio

-7.65

Earnings Per Share (EPS)

-3.51

Revenue

4.76M

Net Profit

-40.83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.xoma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

XOMA Royalty Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XOMA. The last closing price for XOMA Royalty was $27. Over the last year, XOMA Royalty shares have traded in a share price range of $ 13.48 to $ 27.36.

XOMA Royalty currently has 11,638,553 shares outstanding. The market capitalization of XOMA Royalty is $314.24 million. XOMA Royalty has a price to earnings ratio (PE ratio) of -7.65.

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from...

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the...

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and...

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...

Actym Therapeutics Appoints Thomas Smart as CEO

Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to...

XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.35	5.26932084309	25.62	27.05	24.36	19053	25.56432925	CS
4	1.45	5.68181818182	25.52	27.1	21.27	33120	24.27387469	CS
12	1.45	5.68181818182	25.52	27.36	21.27	17897	24.61658686	CS
26	6.97	34.85	20	27.36	18.57	18928	23.89708692	CS
52	10.46	63.3555420957	16.51	27.36	13.48	22323	19.78088784	CS
156	-5.25	-16.2942271881	32.22	37.5	13.48	29429	20.75694957	CS
260	9.55	54.822043628	17.42	46.32	13.48	37172	23.79094474	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
SHOTWSafety Shot Inc	$ 0.41 (115.79%)	7.56k
DATSDatChat Inc	$ 1.89 (81.73%)	54.75M
CYNCYNGN Inc	$ 9.18 (53.77%)	17.79M
SCNIScinai Immunotherapeutics Ltd	$ 5.80 (42.86%)	29.37M
ASLNASLAN Pharmaceuticals Ltd	$ 1.36 (-46.67%)	1.16M
KZIAKazia Therapeutics Ltd	$ 0.5593 (-37.56%)	15.34M
LCFYLocafy Ltd	$ 3.5597 (-36.32%)	584.38k
NAASNaaS Technology Inc	$ 2.82 (-33.02%)	1.94M
ZENVZenvia Inc	$ 1.67 (-26.75%)	658.26k
FFIEFaraday Future Intelligent Electric Inc	$ 0.5152 (22.09%)	217.92M
NVDANVIDIA Corporation	$ 128.44 (-0.62%)	208.32M
SQQQProShares UltraPro Short QQQ	$ 7.46 (-0.67%)	155.14M
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
TSLATesla Inc	$ 252.64 (1.78%)	147.31M